Galmed Pharmaceuticals Ltd.
NASDAQ Capital MarketTotal Valuation
Galmed Pharmaceuticals Ltd. carries a market capitalization of 3.73M, placing it among publicly traded companies globally. Its enterprise value stands at -15.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.73M |
| Enterprise Value | -15.36M |
Share Statistics
Galmed Pharmaceuticals Ltd. currently has 6.58M shares outstanding.
| Shares Outstanding | 6.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.18 |
| P/FCF Ratio | -0.44 |
| P/OCF Ratio | -0.44 |
Financial Position
Galmed Pharmaceuticals Ltd. maintains a current ratio of 6.55, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.55 |
| Quick Ratio | 6.41 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -55.53 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Galmed Pharmaceuticals Ltd.'s stock has declined approximately -54.96689% over the past 52 weeks. The 50-day moving average sits at 0.62, while the 200-day moving average is 0.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | -54.96689% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 0.94 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.51M, while operating income came in at -8.51M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.51M |
| Pretax Income | -10.31M |
| Net Income | -10.31M |
| EBITDA | -8.51M |
| EBIT | -8.51M |
| Earnings Per Share (EPS) | -2.76 |
Balance Sheet
Total book value stands at -207.37M, with working capital of 15.78M providing operational flexibility.
| Cash & Cash Equivalents | 18.16M |
| Total Debt | N/A |
| Net Debt | -3.98M |
| Equity (Book Value) | -207.37M |
| Book Value Per Share | -55.60 |
| Working Capital | 15.78M |
Cash Flow
Galmed Pharmaceuticals Ltd. produced -6.31M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.31M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.31M |
| FCF Per Share | -1.69 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -322.48 |
| FCF Yield | -225.62 |
Stock Splits
Galmed Pharmaceuticals Ltd.'s most recent stock split took place on August 30, 2024 with a 12:1 split ratio.
| Last Split Date | 8/30/2024 |
| Split Ratio | 12:1 |
Scores
Galmed Pharmaceuticals Ltd. posts an Altman Z-Score of -15.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.74 |